KemPharm (KMPH) Price Target Cut to $3.00

KemPharm (NASDAQ:KMPH) had its price target lowered by research analysts at Oppenheimer from $8.00 to $3.00 in a note issued to investors on Thursday, The Fly reports. The firm currently has an “outperform” rating on the specialty pharmaceutical company’s stock. Oppenheimer’s price target would suggest a potential upside of 77.51% from the company’s previous close.

Separately, ValuEngine cut shares of KemPharm from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $6.33.

Shares of KemPharm stock opened at $1.69 on Thursday. KemPharm has a 52-week low of $1.15 and a 52-week high of $7.15. The firm has a market capitalization of $48.20 million, a PE ratio of -0.68 and a beta of 1.63.

KemPharm (NASDAQ:KMPH) last announced its quarterly earnings data on Tuesday, May 14th. The specialty pharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.46). As a group, analysts forecast that KemPharm will post -1.39 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the business. Janney Montgomery Scott LLC purchased a new stake in KemPharm during the 4th quarter valued at $44,000. Change Path LLC purchased a new stake in KemPharm during the 4th quarter valued at $67,000. Wedbush Securities Inc. purchased a new stake in KemPharm during the 1st quarter valued at $72,000. Northern Trust Corp boosted its position in KemPharm by 34.0% during the 4th quarter. Northern Trust Corp now owns 43,445 shares of the specialty pharmaceutical company’s stock valued at $78,000 after buying an additional 11,014 shares during the period. Finally, BlackRock Inc. boosted its position in KemPharm by 25.0% during the 4th quarter. BlackRock Inc. now owns 90,426 shares of the specialty pharmaceutical company’s stock valued at $161,000 after buying an additional 18,079 shares during the period. 33.59% of the stock is owned by institutional investors and hedge funds.

About KemPharm

KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder.

Recommended Story: What is the S&P 500 Index?

The Fly

Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit